Monday, August 31, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· March 26, 2026

DBV Technologies publie ses résultats financiers annuels 2025 et fait le point sur ses activités

View original at globenewswire.com
“Trésorerie et équivalents de trésorerie de 194 millions de dollars au 31 décembre 2025”
Verbatim excerpt from the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • DBV is pleased with the progress made in strengthening capabilities and building a company ready for the launch of Viaskin Peanut

    60% confidence

  • These estimates are based on the Company's current forecasts and exclude any additional expenses related to programs other than Viaskin Peanut, or resulting from potential licensing or acquisition operations of additional product candidates or technologies

    60% confidence

  • The Company may have based these estimates on assumptions that could prove to be inaccurate, and could consequently use its resources more quickly than anticipated

    60% confidence

  • Management estimates that the Company has sufficient resources to fund operations through the second quarter of 2027

    60% confidence

  • DBV remains firmly committed to making Viaskin Peanut available to children aged 1 to 7 years allergic to peanuts

    60% confidence

  • We approached 2025 focused on strengthening the company's financial position, completing the VITESSE study, launching the COMFORT Toddlers study, and preparing for the BLA submission and potential commercial launch in the United States

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI's Trust Gap: Microsoft-Mistral Ecosystem Expansion Meets a Governance Deficit in Agentic Adoption
Microsoft is deepening its AI platform bet through simultaneous moves — expanding its Mistral partnership (Copilot Studio, Foundry, European infrastructure capacity) and deepening enterprise AI governance ties with Manulife — just as independent research (Google Cloud, VentureBeat, Box) shows enterprises racing toward agentic AI adoption (100% planned within two years) while data access and trust in agent decisions lag badly (average 45% data access, only ~half trust agent outputs). The result is a structural mismatch between platform-vendor momentum and enterprise readiness to actually govern and trust the agents being deployed.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
Same entity (Morgan Stanley & Co. LLC), same metric (net_income), same fiscal period (Q1 2026), same observation date (2026-03-31), but vastly different values: $5.567 billion vs. $5.57. These cannot coexist for the same time period. Fact B appears to be a data entry error (possible missing decimal placement: 5.57 should likely be 5,567,000,000 or a per-share figure incorrectly entered as total).
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,257 source documents archived
Query this data → isubstrate.com